Dr Shanu Modi talks to ecancer about her findings from a phase 3 randomised study, known as DESTINY-Breast04, investigating trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-low unresectable and or metastatic breast cancer.
She discusses and outlines the methodology of the study.
Then goes onto to explain the results and key findings which were that DESTINY-Breast 04 is the first phase 3 trial of a HER-2 directed therapy in patients with HER2-low mBC to show a statistically meaningful benefit in PFS and OS compared to the standard of care treatment, regardless of HR status, with a generally manageable safety profile.
